{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:12:18Z","timestamp":1772741538445,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11095-025-04013-z","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:09:50Z","timestamp":1768507790000},"page":"381-393","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Forecasting the Biological Effect of PEGylated-rHuEPO Candidates in Chronic Kidney Disease Patients using a Middle-out Translation Approach"],"prefix":"10.1007","volume":"43","author":[{"given":"Gledys","family":"Reynaldo-Fernandez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leyanis","family":"Rodriguez-Vera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Amaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquin","family":"Soloz\u00e1bal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Duconge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Mangas-Sanjuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I\u00f1aki F.","family":"Troconiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francine Johansson","family":"Azeredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2636-1889","authenticated-orcid":false,"given":"Valvanera","family":"Vozmediano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"4013_CR1","doi-asserted-by":"crossref","unstructured":"Kovesdy\u202fCP. Epidemiology of chronic kidney disease: an update 2022.\u202fKidney\u202fInt\u202fSuppl.\u202f2022;12:7\u201311.","DOI":"10.1016\/j.kisu.2021.11.003"},{"issue":"3","key":"4013_CR2","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1016\/S2214-109X(23)00570-3","volume":"12","author":"AK Bello","year":"2024","unstructured":"Bello AK, Okpechi IG, Levin A, Ye F, Damster S, Arruebo S, et al. An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob Health. 2024;12(3):e382\u201395.","journal-title":"Lancet Glob Health"},{"key":"4013_CR3","doi-asserted-by":"crossref","unstructured":"Deng L, Guo S, Liu Y, Zhou Y, Liu Y, Zheng X, et al. Global, regional, and national burden of chronic kidney disease and its underlying etiologies from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021. BMC Public Health. 2025;25:636.","DOI":"10.1186\/s12889-025-21851-z"},{"issue":"4","key":"4013_CR4","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4):S117-314.","journal-title":"Kidney Int"},{"key":"4013_CR5","doi-asserted-by":"crossref","unstructured":"Arantes LH, Crawford J, Gascon P, Latymer M, Launay-Vacher V, Rolland C, et al. A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia. Crit Rev Oncol Hematol. 2018;129:79\u201390.","DOI":"10.1016\/j.critrevonc.2018.06.010"},{"key":"4013_CR6","doi-asserted-by":"crossref","unstructured":"Portol\u00e9s J, Mart\u00edn L, Broseta JJ, Cases A. Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents. Front Med (Lausanne). 2021;8:642296.","DOI":"10.3389\/fmed.2021.642296"},{"issue":"1","key":"4013_CR7","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.30574\/wjarr.2024.21.1.0382","volume":"21","author":"EC Anyanwu","year":"2024","unstructured":"Anyanwu EC, Arowoogun JO, Odilibe IP, Akomolafe O, Onwumere C, Ogugua JO. The role of biotechnology in healthcare: A review of global trends. World J Adv Res Rev. 2024;21(1):2740\u201352.","journal-title":"World J Adv Res Rev."},{"key":"4013_CR8","doi-asserted-by":"crossref","unstructured":"Kuragano T. Treatment of anemia associated with chronic kidney disease: plea for considering physiological erythropoiesis. Int J Mol Sci. 2024;25:7322.","DOI":"10.3390\/ijms25137322"},{"key":"4013_CR9","doi-asserted-by":"crossref","unstructured":"Badura K, Janc J, W\u0105sik J, Gnitecki S, Skwira S, M\u0142ynarska E, et al. Anemia of chronic kidney disease\u2014a narrative review of its pathophysiology, diagnosis, and management. Biomedicines. 2024;12:1191.","DOI":"10.3390\/biomedicines12061191"},{"key":"4013_CR10","first-page":"161","volume":"7","author":"AM Sinclair","year":"2013","unstructured":"Sinclair AM. Erythropoiesis stimulating agents: approaches to modulate activity. Biologics. 2013;7:161-174.","journal-title":"Biologics: Targets Ther."},{"key":"4013_CR11","doi-asserted-by":"crossref","unstructured":"Zaman R, Islam RA, Ibnat N, Othman I, Zaini A, Lee CY, et al. Current strategies in extending half-lives of therapeutic proteins. J Control Release. 2019;301:176\u2013189","DOI":"10.1016\/j.jconrel.2019.02.016"},{"key":"4013_CR12","unstructured":"Roche Genentech Inc. MIRCERA. HIGHLIGHTS OF PRESCRIBING INFORMATION [package insert] South San Francisco (CA): Genentech, Inc. Available at: [Internet]. 2014 [cited 2025 Sep 11]. Available from: https:\/\/www.fda.gov\/drugsatfda. Accessed 12 July 2025."},{"key":"4013_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/IJNRD.S23447","volume":"5","author":"N Ohashi","year":"2012","unstructured":"Ohashi N, Sakao Y, Yasuda H, Kato A, Fujigaki Y. Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease. Int J Nephrol Renovasc Dis. 2012;5:53\u201360.","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"4013_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nchem.1230","volume":"4","author":"MC Parrott","year":"2012","unstructured":"Parrott MC, DeSimone JM. Drug delivery: relieving PEGylation. Nat Chem. 2012;4(1):13-14.","journal-title":"Nat Chem."},{"key":"4013_CR15","doi-asserted-by":"crossref","unstructured":"Zaghmi A, Mendez-Villuendas E, Greschner AA, Liu JY, de Haan HW, Gauthier MA. Mechanisms of activity loss for a multi-PEGylated protein by experiment and simulation. Mater Today Chem. 2019;12:121\u2013131","DOI":"10.1016\/j.mtchem.2018.12.007"},{"key":"4013_CR16","doi-asserted-by":"crossref","unstructured":"Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005;10(21):1451\u20131458","DOI":"10.1016\/S1359-6446(05)03575-0"},{"key":"4013_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21278","author":"C Simone Fishburn","year":"2008","unstructured":"Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci. 2008;97(10):4167-4183","journal-title":"J Pharm Sci"},{"key":"4013_CR18","doi-asserted-by":"crossref","unstructured":"Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2(3):214\u201321.","DOI":"10.1038\/nrd1033"},{"key":"4013_CR19","doi-asserted-by":"publisher","DOI":"10.1039\/C5MB00857C","author":"E Hoffmann","year":"2016","unstructured":"Hoffmann E, Streichert K, Nischan N, Seitz C, Brunner T, Schwagerus S, et al. Stabilization of bacterially expressed erythropoietin by single site-specific introduction of short branched PEG chains at naturally occurring glycosylation sites. Mol Biosyst. 2016. https:\/\/doi.org\/10.1039\/C5MB00857C.","journal-title":"Mol Biosyst"},{"key":"4013_CR20","doi-asserted-by":"crossref","unstructured":"Makharadze D, del Valle LJ, Katsarava R, Puiggal\u00ed J. The art of PEGylation: from simple polymer to sophisticated drug delivery system. Int J Mol Sci. 2025;26(7):3102.","DOI":"10.3390\/ijms26073102"},{"issue":"5","key":"4013_CR21","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/cpt.3006","volume":"114","author":"S Marshall","year":"2023","unstructured":"Marshall S, Ahamadi M, Chien J, Iwata D, Farkas P, Filipe A, et al. Model-Informed Drug Development: Steps Toward Harmonized Guidance. Clin Pharmacol Ther. 2023;114(5):954\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"4013_CR22","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). M15: General principles for model-informed drug development. Geneva: ICH; 2024."},{"key":"4013_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00997","author":"H Zou","year":"2020","unstructured":"Zou H, Banerjee P, Leung SSY, Yan X. Application of pharmacokinetic-pharmacodynamic modeling in drug delivery: development and challenges. Front Pharmacol. 2020;11:997","journal-title":"Front Pharmacol"},{"key":"4013_CR24","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.1365-2125.2005.02560.x","volume":"60","author":"L Aarons","year":"2005","unstructured":"Aarons L. Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed. Br J Clin Pharmacol. 2005;60(6):581-583.","journal-title":"Brit J Clin Pharmacol."},{"key":"4013_CR25","doi-asserted-by":"crossref","unstructured":"Salim EL, Kristensen K, Chopda G, Sj\u00f6gren E. Whole-body physiologically based pharmacokinetic-pharmacodynamic modeling for interspecies translation and mechanistic characterization of plasma and tissue disposition of GalNAc-siRNAs. Pharmaceutics. 2025;17(9):1154.","DOI":"10.3390\/pharmaceutics17091154"},{"issue":"3","key":"4013_CR26","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cpt.3289","volume":"116","author":"K Rowland Yeo","year":"2024","unstructured":"Rowland Yeo K, Gil Berglund E, Chen Y. Dose Optimization Informed by PBPK Modeling: State-of-the Art and Future. Clin Pharmacol Ther. 2024;116(3):563\u201376.","journal-title":"Clin Pharmacol Ther"},{"key":"4013_CR27","first-page":"13","volume":"12","author":"R Michelet","year":"2023","unstructured":"Michelet R, Bindellini D, Melin J, Neumann U, Blankenstein O, Huisinga W, et al. Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach. Front Pharmacol. 2023;12:13.","journal-title":"Front Pharmacol"},{"key":"4013_CR28","doi-asserted-by":"crossref","unstructured":"Jolling K, Perez Ruixo JJ, Hemeryck A, Vermeulen A, Greway T. Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. Eur J Pharm Sci. 2005;24(5):465\u2013475","DOI":"10.1016\/j.ejps.2005.01.002"},{"key":"4013_CR29","doi-asserted-by":"crossref","unstructured":"Woo S, Jusko WJ. Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metab Dispos. 2007;35(9):1672\u20138.","DOI":"10.1124\/dmd.107.015248"},{"issue":"120","key":"4013_CR30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejps.2018.04.047","volume":"30","author":"G Reynaldo-Fern\u00e1ndez","year":"2018","unstructured":"Reynaldo-Fern\u00e1ndez G, Soloz\u00e1bal J, Amaro D, Fern\u00e1ndez-S\u00e1nchez EM, Rodr\u00edguez-Vera L, Bermejo M, et al. Semi-mechanistic Pharmacokinetic\/Pharmacodynamic model of three pegylated rHuEPO and ior\u00aeEPOCIM in New Zealand rabbits. Eur J Pharm Sci. 2018;30(120):123\u201332.","journal-title":"Eur J Pharm Sci"},{"key":"4013_CR31","doi-asserted-by":"crossref","unstructured":"Jones SS, D\u2019Andrea AD, Zyxwvu L, Haines L, Wong GG. Human erythropoietin receptor: cloning, expression, and biologic characterization. Blood. 1990;76(1):31\u201335","DOI":"10.1182\/blood.V76.1.31.bloodjournal76131"},{"key":"4013_CR32","unstructured":"European Medicines Agency. Mircera \u2013 EPAR: Scientific Discussion [Internet]. London; 2007 [cited 2025 Sep 13]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion\/mircera-epar-scientific-discussion_en.pdf. Accessed 13 Sep 2025."},{"issue":"5","key":"4013_CR33","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1159\/000502525","volume":"44","author":"JH Li","year":"2019","unstructured":"Li JH, Luo JF, Jiang Y, Ma YJ, Ji YQ, Zhu GL, et al. Red Blood Cell Lifespan Shortening in Patients with Early-Stage Chronic Kidney Disease. Kidney Blood Press Res. 2019;44(5):1158\u201365.","journal-title":"Kidney Blood Press Res"},{"issue":"11","key":"4013_CR34","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1093\/ndt\/gfab318","volume":"37","author":"V Perkovic","year":"2022","unstructured":"Perkovic V, Blackorby A, Cizman B, Carroll K, Cobitz AR, Davies R, et al. The ASCEND-ND trial: study design and participant characteristics. Nephrol Dial Transplant. 2022;37(11):2157\u201370.","journal-title":"Nephrol Dial Transplant"},{"key":"4013_CR35","unstructured":"World Health Organization. Guideline on haemoglobin cutoffs to define anaemia in individuals and populations. Geneva: World Health Organization; 2024. p. 57"},{"key":"4013_CR36","doi-asserted-by":"crossref","unstructured":"Helmlinger G, Al-Huniti N, Aksenov S, Peskov K, Hallow KM, Chu L, et al. Drug-disease modeling in the pharmaceutical industry\u2014where mechanistic systems pharmacology and statistical pharmacometrics meet. Eur J Pharm Sci. 2017;109S:S39\u2013S46.","DOI":"10.1016\/j.ejps.2017.05.028"},{"key":"4013_CR37","doi-asserted-by":"crossref","unstructured":"Krzyzanski W, Wyska E. Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers. Naunyn Schmiedebergs Arch Pharmacol. 2008;377(4-6):637\u201345.","DOI":"10.1007\/s00210-007-0225-z"},{"key":"4013_CR38","doi-asserted-by":"crossref","unstructured":"El-Komy MH, Widness JA, Veng-Pedersen P. Pharmacokinetic analysis of continuous erythropoietin receptor activator disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology. Drug Metab Dispos. 2011;39(4):603\u20139.","DOI":"10.1124\/dmd.110.036236"},{"key":"4013_CR39","doi-asserted-by":"crossref","unstructured":"Wu N, Widness JA, Yan X, Veng-Pedersen P, An G. A full target-mediated drug disposition (TMDD) model to explain the changes in recombinant human erythropoietin (rhEpo) pharmacokinetics in patients with different bone marrow integrity following hematopoietic transplantation. J Pharm Sci. 2022;111(9):2620\u20132629","DOI":"10.1016\/j.xphs.2022.06.003"},{"key":"4013_CR40","doi-asserted-by":"crossref","unstructured":"Fleming PJ, Correia JJ, Fleming KG. The molecular basis for hydrodynamic properties of PEGylated human serum albumin. Biophys J. 2024;123(16):2379\u20132391.","DOI":"10.1016\/j.bpj.2024.05.019"},{"key":"4013_CR41","doi-asserted-by":"crossref","unstructured":"Akbarzadehlaleh P, Mirzaei M, Mashahdi-Keshtiban M, Heidari HR. The effect of length and structure of attached polyethylene glycol chain on hydrodynamic radius, and separation of PEGylated human serum albumin by chromatography. Adv Pharm Bull. 2021;11(4):728\u2013738.","DOI":"10.34172\/apb.2021.082"},{"key":"4013_CR42","doi-asserted-by":"crossref","unstructured":"Cahn D, Duncan GA. High-density branched PEGylation for nanoparticle drug delivery. Cell Mol Bioeng. 2022;15(5):355\u2013366.","DOI":"10.1007\/s12195-022-00727-x"},{"key":"4013_CR43","doi-asserted-by":"crossref","unstructured":"Jelkmann W. Efficacy of recombinant erythropoietins: is there unity of international units? Nephrol Dial Transplant. 2009;24(5):1366\u20138","DOI":"10.1093\/ndt\/gfp058"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-04013-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-025-04013-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-04013-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T19:38:47Z","timestamp":1772739527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-025-04013-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4013"],"URL":"https:\/\/doi.org\/10.1007\/s11095-025-04013-z","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}